Africa: sequence 100,000 species to safeguard biodiversity
By ThankGod Echezona Ebenezer et. al,
Nature
| 03. 15. 2022
Sleeper fish (Bostrychus africanus) are a staple food in West Africa. Harvesting them provides an important source of income for hundreds of communities across the Gulf of Guinea in the Atlantic Ocean. Yet little is known about the genetics of this fish — information that is crucial to safeguarding its genetic diversity, and to enhancing its resilience in the face of climate change and other pressures.
This situation is all too familiar across Africa. Consider orphan crops, which have a crucial role in regional food security, even though they are not typically traded internationally. More than 50% of these have not had their genomes sequenced — from the fluted pumpkin (Telfairia occidentalis) to the marama bean (Tylosema esculentum). The same is true of more than 95% of the continent’s known endangered species (see ‘Africa’s neglected genomes’).
What’s more, by our estimate, around 70% of the 35 or so projects that have focused on studying, conserving or improving biological diversity in Africa over the past 15 years have been led from outside the continent. In... see more
Related Articles
By Sarah Zhang, The Atlantic | 06.22.2022
Photo by ANIRUDH on Unsplash
In October 2019, Jordan Janz became the first person in the world to receive an experimental therapy for cystinosis, a rare genetic disease. The treatment was physically grueling. Doctors extracted blood stem cells from Janz’s...
By Ian Sample , The Guardian | 06.22.2022
More than half the UK backs the idea of rewriting the DNA of human embryos to prevent severe or life-threatening diseases, according to a survey.
Commissioned by the Progress Educational Trust (PET), a fertility and genomics charity, the Ipsos poll...
By Fiorella Valdesolo, WSJ Magazine | 06.08.2022
“Where is the we?” It’s the question that was the driving force for Vida Delrahim and Ronit Menashe when they created WeNatal, a new brand of prenatal supplements that aims to be more inclusive. In the process of trying...
By Michael Le Page, New Scientist | 06.16.2022
CRISPR gene-editing trials for treating sickle cell disease and beta thalassaemia are being extended to include children aged under 12 after the therapies proved successful in ongoing trials involving people aged between 12 and 35. The aim is to treat...